NCT04161118View on ClinicalTrials.gov

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

CTL019

IV Infusion

Trial Locations (2)

45147

Universitätsklinik Essen, Klinik für Hämatologie, Essen

50937

University of Cologne, Cologne

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Cologne

OTHER